5th NASH Summit 2021

Deepening Understanding of Early, Translational and Late Stage Clinical Science to Support NASH Candidate Entry to Market

Are you ready to discover the knowledge you need to radically transform your NASH drug development strategy? Then look no further – returning with a revitalized agenda and re-energized speaker faculty, the NASH Summit is back!

Masterfully combining the hottest insights on NASH from 65+ strong speaker faculty, including 45+ brand new speakers from the FDA, EMA, Takeda, Eli Lilly, Gilead, Pfizer, AstraZeneca, Ionis, Novo Nordisk and more, the 5th NASH Summit is your best opportunity to unite with fellow NASH drug developers to gain critical updates on the trailblazing research you need to meaningfully reassess your therapeutic approach and optimize your pipeline strategy for the future.

From evaluating the potential of the gut-liver axis as a therapeutic target and analyzing the nuances of designing models which accurately illustrate cirrhosis complications to discovering which physiological factors you must monitor to maximize the success of your clinical trials, this is the only end-to-end forum dedicated to helping industry translate scientific advancements to actionable insights in order to achieve more innovative and clinically effective NASH drug development.

Join 3 streams, a focused seminar day and 6 workshops of unparalleled content to keep your companies interests in NASH up to date and aligned with the new cadence of this exciting field.

Want to learn more about our brand new 2021 agenda and expert speaker faculty? Download the Full Event Guide Here

Hear from 65+ speakers, including:

Abbas Bandukwala

Science Policy Analyst, Biomarker Qualification Program

FDA

Axel Haupt

Vice President for Diabetes Clinical Investigation & Insulin & Incretin Research

Eli Lilly

James Trevaskis

Senior Director of Biology & Head of Fibrosis Research

Gilead

Juliette Chen

Director – Global Evidence and Outcomes

Takeda

Paul Monga

Assistant Dean, Vice Chair & Endowed Chair of Experimental Pathology

University of Pittsburgh

Alessandro Pocai

Senior Director for Cardiovascular & Metabolic Research

Janssen

Bart Staels

Professor

University of Lille

Becky Taub, Madrigal Pharmaceuticals, NASH Conference Speaker

Becky Taub

Founder, Director, CEO & President

Madrigal Pharmaceuticals

Daniel Lindén

Senior Principal Scientist

AstraZeneca

Michael Cooreman

Chief Medical Officer

Inventiva Pharma

What You Will Gain from Attending:

 

  • Networking: Network one-to-one with 350 other key decision-makers across multiple perspectives prioritizing NASH. Meet through dedicated 1-2-1 networking sessions and collaborate with discovery, translational and safety scientists, as well as clinical program and market access leads and scientists developing innovative preclinical and non-invasive technologies.
  • Actionable Insights: Hear first-hand how the latest scientific understanding is being applied to pipeline progress enabling you to benchmark your decisions against others in the field and gain innovative foresight to address challenges before you reach them.
  • Sharing your data: Present your own work to your peers and thought leaders to gain critical and candid feedback that could be pivotal to opening up partnerships and changing the trajectory of your program.
  • Harmonize your thoughts with the field: With over 170 organizations gathering to present, discuss, and share their expectations for NASH, you will align your own thinking with that of the rest of the field and identify the niche that gives you maximum return on investment.

A Glimpse of What to Expect

"This was unlike any scientific meeting I have ever been to. Everyone who attended was interested in some aspect of drug development for NASH. I truly enjoyed the "applied science" focus of the meeting as it helped me where I most needed the help. The opportunity to network and learn informally in the poster session and during receptions was excellent."

 

Other Events in the Series